Pharmaleads to Present PL265 for Ocular Pain Results at the ARVO 2017 Annual Meeting in Baltimore

Source: Pharmaleads

Pharmaleads announced that a poster presentation on its Dual ENKephalinase Inhibitor (DENKI) PL265 has been accepted for presentation at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting, which is being held from May 7-11 in Baltimore.

Pharmaleads is a leader in the understanding of the role of enkephalins in the management of local pain relief. Enkephalins are degraded by two enzymes, the enkephalinases NEP and APN, from the zinc-metallopeptidase family. Pharmaleads medicinal chemistry expertise has allowed the company to develop drugs called DENKIs that are able to improve pain management by increasing the local concentrations of enkephalins, inhibiting the two enzymes responsible for their degradation.

PL265, one of the two drugs in clinical development at Pharmaleads, is being developed as eye drops for ophthalmic pain/dry eye syndrome.

The poster session details are:

Poster No.:   B0059

Program Number: 5172

Poster Title: Dual enkephalinase inhibitor (DENKI) PL265: a novel topical treatment for ocular pain?

Presentation Time:  Thursday, May 11, 8:30 AM -10:130 AM

Session: Toxicology; hypoxia; ischemia; oxidative stress; corneal disease

“We are delighted to have the opportunity to present at this year’s ARVO Meeting. This is exciting news for our company as it is the first time we will be presenting at ARVO, one of the largest and most highly respected vision research organizations in the world," Thierry Bourbié, CEO of Pharmaleads, said in a company news release. "The data being presented, which assesses the anti-nociceptive effect of PL265 in experimental models of corneal pain, clearly supports the potential of DENKIs in the treatment of ophthalmic eye diseases and conditions.”

“Ocular pain is a significant indication where there is a strong demand for improved treatment options. We believe that our DENKIs, the only drug candidates in clinical development that target the two enzymes responsible for the degradation of enkephalins, will provide an analgesia similar to that of opiates but without their highly troublesome side-effects," Mr. Thierry added.

Pharmaleads is looking for a pharma partner to support the development of PL265 in the ophthalmology field.

Pharmaleads is also developing an oral formulation of PL265 for the treatment of neuropathic pain. PL265 has completed phase I single ascending dose (SAD) clinical trials and demonstrated good safety and tolerability. Pharmaleads anticipates to start a phase 1/2a clinical trial with PL265 in ocular pain in 2018.

Related Content